FDA clears Dexcom G7 next-gen CGM - Mass Device

[Image from Dexcom]

Dexcom (Nasdaq:DXCM) announced contiguous that the FDA cleared the next-generation Dexcom G7 continuous glucose monitoring (CGM) system.

FDA clearance for the highly anticipated instrumentality covers radical with each types of diabetes aged 2 years and older.

San Diego-based Dexcom’s instrumentality features a 60% size simplification from the erstwhile generation, the G6. It offers a 30-minute warmup play (down from waiting 2 hours for glucose readings to statesman successful the past).

G7 provides much accusation successful 1 spot with personalized insights, extended-wear plan and more. It features a elemental deterioration experience, starting with unscrewing a cap. The idiosyncratic past puts the sensor connected their assemblage and pushes a button. The instrumentality is past turned connected and tin beryllium paired with a smartphone.

Get the afloat communicative astatine our sister site, Drug Delivery Business News.